Idiopathic Pulmonary Fibrosis – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by the thickening and stiffening of tissues in the lungs. Although the prognosis for patients diagnosed with IPF is poor (survival of three to five years after diagnosis in most cases), various therapies can relieve symptoms, prevent further lung scarring, and improve patients’ quality of life. Different drug classes are used to target the respective physiological mechanisms. For example, tyrosine kinase inhibitors (e.g., nintedanib [Boehringer Ingelheim’s Ofev]) block the action of enzymes that cause fibrosis, while antifibrotic agents such as pirfenidone (Roche/Genentech’s Esbriet) reduce lung fibrosis by downregulating the production of growth factors. This analysis of patient-level claims data provides insight into the dynamics of the IPF treatment landscape.
Questions answered
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed IPF patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed IPF patients?
- How have nintedanib (Boehringer Ingelheim’s Ofev) and pirfenidone (Roche / Genentech’s Esbriet) been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of IPF patients receive drug therapy after diagnosis, and how quickly? What percentage of patients progress to later lines of therapy after diagnosis?
- What percentage of IPF patients are treated with monotherapy vs. combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Product description
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Boehringer Ingelheim, Roche / Genentech.
Key drugs: Azathioprine, benralizumab, nintedanib, pirfenidone, sildenafil.
Solution enhancement
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.
Table of contents
- Idiopathic Pulmonary Fibrosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
- Treatment Algorithms CDA Idiopathic Pulmonary Fibrosis US April 2023
- Treatment Algorithms CDA Idiopathic Pulmonary Fibrosis 2023 Dashboard
Muthana Sweis, M.P.H., is an analyst on the Infectious, Niche, and Rare Diseases team at Clarivate. He has authored content for indications such as emerging vaccines, essential thrombocythemia, idiopathic pulmonary fibrosis, and myelodysplastic syndromes. He earned his master’s degree in public health from DePaul University.